JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Home・Aandelen Lijst・Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc

Gesloten

SectorGezondheidszorg

24.75 0.32

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

24.66

Max

24.81

Belangrijke statistieken
By Trading Economics
Inkomsten	51M -129M
Verkoop	207M
Winstmarge	-62.319
Werknemers	1,371
EBITDA	8.8M -105M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+111.71% upside

Dividenden
By Dow Jones
Volgende Winsten	5 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	379M 2.4B
Vorige openingsprijs	24.43
Vorige sluitingsprijs	24.75

Nieuwssentiment

By Acuity

19%

81%

35 / 347 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

32.76 / 39.24 Steun & Weerstand

Ultragenyx Pharmaceutical Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

1 mei 2026, 21:36 UTC

Acquisities, Fusies, Overnames

FTC Requires 365 Retail Markets to Divest Micromarket Kiosk Business to Clear Acquisition of Cantaloupe

1 mei 2026, 20:40 UTC

Acquisities, Fusies, Overnames

Meta Platforms Acquires Humanoid Robot Startup Assured Robot Intelligence

1 mei 2026, 18:37 UTC

Belangrijke Marktbewegers

Senseonic Shares Slide on Underwritten Offering Price

1 mei 2026, 16:46 UTC

Belangrijke Marktbewegers

Stellantis, Ferrari Fall on Trump Plan to Increase Tariff on European Cars, Trucks

2 mei 2026, 19:57 UTC

Acquisities, Fusies, Overnames

Berkshire CEO Greg Abel Takes the Stage, Making a Case for the Post-Buffett Era -- 3rd Update

2 mei 2026, 15:24 UTC

Winsten

Berkshire CEO Greg Abel Takes the Stage, Talks Through Quarterly Results -- Update

2 mei 2026, 12:46 UTC

Winsten

Acquisities, Fusies, Overnames

Berkshire Profits More Than Double on Gains in Insurance, Railroad, Energy Businesses -- WSJ

2 mei 2026, 08:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

1 mei 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

1 mei 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

1 mei 2026, 20:42 UTC

Winsten

Western Digital Beats Earnings Estimates. The Stock Is Falling Anyway. -- Barrons.com

1 mei 2026, 19:33 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

1 mei 2026, 19:33 UTC

Marktinformatie

Change in Fed Leadership May Hamper Crypto Rebound -- Market Talk

1 mei 2026, 19:18 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Rises for Second Consecutive Week Amid Middle East Standoff -- Market Talk

1 mei 2026, 19:13 UTC

Marktinformatie

Natural Gas Rises as Markets Wait for Warmer Temperatures -- Market Talk

1 mei 2026, 18:36 UTC

Winsten

3 Takeaways From Apple Earnings. The Stock Is Surging. -- Barrons.com

1 mei 2026, 18:35 UTC

Winsten

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1 mei 2026, 18:28 UTC

Winsten

These Stocks Are Today's Movers: Apple, Sandisk, Roblox, Intel, Ferrari, Atlassian, Western Digital, Clorox, Paramount Skydance, and More -- Barrons.com

1 mei 2026, 18:27 UTC

Marktinformatie

Gold and Silver Higher for the Day, Lower For The Week -- Market Talk

1 mei 2026, 18:14 UTC

Acquisities, Fusies, Overnames

Barclays Completes Acquisition of Best Egg

1 mei 2026, 18:04 UTC

Winsten

The First $6 Trillion Company May Not Be Nvidia -- Barrons.com

1 mei 2026, 17:43 UTC

Marktinformatie

Home Sales in San Francisco Jump 22.2% in March -- Market Talk

1 mei 2026, 17:37 UTC

Marktinformatie

Crypto 'Fear and Greed Index' Returns to Neutral Reading After Brief Dip -- Market Talk

1 mei 2026, 17:30 UTC

Marktinformatie

Winsten

Apple's 2Q Print, 3Q Guide Set Up Stock to Outperform -- Market Talk

1 mei 2026, 17:28 UTC

Marktinformatie

Winsten

Apple's Shift From Net Cash Neutral Goal Seen as Cryptic Signal -- Market Talk

1 mei 2026, 17:21 UTC

Marktinformatie

Winsten

Apple Seen Absorbing Higher Memory Costs -- Market Talk

1 mei 2026, 17:19 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

U.S. Oil Rig Count Rises by 1 to 408 -- Market Talk

1 mei 2026, 16:38 UTC

Marktinformatie

Institutional Markets Begin to Trade on Event Contracts -- Market Talk

1 mei 2026, 16:23 UTC

Acquisities, Fusies, Overnames

Paramount Skydance Gets a Double Upgrade. It's the Warner Bros. Deal. -- Barrons.com

1 mei 2026, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Ultragenyx Pharmaceutical Inc Prognose

Koersdoel

By TipRanks

111.71% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 52.44 USD 111.71%

Hoogste 84 USD

Laagste 25 USD

Gebaseerd op 18 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ultragenyx Pharmaceutical Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

18 ratings

Buy

Hold

Sell

Gebaseerd op 18 analisten die aandelenratings hebben gegeven aan Ultragenyx Pharmaceutical Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

32.76 / 39.24Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

35 / 347 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.